Astellas Pharma Competitors and Similar CompaniesClear all
Bayer's competitors and similar companies include Immunomedics, Urovant Sciences, Hetero and Viatris.
 Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. |  Hetero Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs. |  Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. | ||
Founding Date | Founding Date 1863 | Founding Date 1982 | Founding Date 2016 | Founding Date 1993 | Founding Date 2020 |
Type | Type Public | Type Subsidiary | Type Subsidiary | Type Private | Type Public |
Tags | |||||
Locations | Locations Morris Plains, US HQ | Locations Irvine, US HQ Basel, CH | Locations Hyderabad, IN HQ Norwest, AU Sao Paulo, BR Beijing, CN Nanjing Shi, CN Nanjing Shi, CN Bogotá, CO see more | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | |
Employees | Employees 92,8152% decrease | Employees 1041% decrease | Employees 3950% increase | Employees 6,5492% increase | Employees 38,0003% increase |
Valuation ($) | Valuation ($) 27.1 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 14 b |
Financial | |||||
Revenue (est.) | Revenue (est.) €46.6b (FY, 2024) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $14.7b (FY, 2024) |
Cost of goods | Cost of goods €12b (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $9.1b (FY, 2024) |
Gross profit | Gross profit €35.8b (FY, 2024) | Gross profit $295k (FY, 2019) | Gross profit N/A | Gross profit N/A | Gross profit $5.6b (FY, 2024) |
Net income | Net income (€2.5b) (FY, 2024) | Net income ($357.3m) (FY, 2019) | Net income ($146.7m) (FY, 2020) | Net income N/A | Net income ($634.2m) (FY, 2024) |
Operating ⚠ | |||||
Countries | Countries 83 (FY, 2021) | Countries N/A | Countries N/A | Countries 126 (Jan, 2021) | Countries 165 (Q1, 2023) |
Patent Applications (US) | Patent Applications (US) N/A | Patent Applications (US) 230 (Sep, 2022) | Patent Applications (US) N/A | Patent Applications (US) 23 (Jan, 2021) | Patent Applications (US) N/A |
Patents (US) | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) N/A | Patents (US) 38 (Jan, 2021) | Patents (US) N/A |
Products | Products N/A | Products N/A | Products N/A | Products 200 (Jan, 2021) | Products 4 (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised $ 3.5b | Total funding raised $ 30m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Immunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyUrovant Sciences
HQ
Irvine, US
Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.
View companyHetero
HQ
Hyderabad, IN
Employees
6,549↑ 2% increase
Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs.
View companyViatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View company